Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 327 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: University of Michigan Rogel Cancer Center Clear all
Completed No phase listed Observational Results available

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients

NCT01814397
View directory record Official record
Conditions
Breast Cancer, Pain, Arthralgia
Interventions
Anastrozole, exemestane, letrozole
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 13, 2026, 8:23 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

NCT05956041
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome
Interventions
Pembrolizumab, Mogamulizumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Completed No phase listed Observational

Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy

NCT02496260
View directory record Official record
Conditions
Breast Cancer
Interventions
Research Cardiac MRI, Biomarkers
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Not applicable Interventional Results available

Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

NCT01028352
View directory record Official record
Conditions
Breast Cancer
Interventions
Duloxetine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 13, 2026, 8:23 PM EDT
Recruiting Phase 2 Interventional

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

NCT05038332
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ultra-hypofractionated radiation therapy, Moderately Hypo-fractionated Radiation Therapy
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes

NCT06927947
View directory record Official record
Conditions
Hereditary Malignant Neoplasm, Hereditary Neoplastic Syndrome
Interventions
Communication Intervention, Health Promotion and Education, Informational Intervention, Survey Administration
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Phase 1 Interventional

Curcumin for the Prevention of Colon Cancer

NCT00027495
View directory record Official record
Conditions
Colorectal Cancer
Interventions
curcumin
Dietary Supplement
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional Results available

Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients

NCT00982995
View directory record Official record
Conditions
Nausea, Vomiting, Terminally Ill
Interventions
Palonosetron
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers

NCT02409121
View directory record Official record
Conditions
Leukemia, Lymphoma, Brain Tumor
Interventions
Education information system
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
10 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

NCT00393796
View directory record Official record
Conditions
Bladder Cancer
Interventions
SUTENT, Placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Early Phase 1 Interventional

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

NCT02463994
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
MPDL3280A, Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Not applicable Interventional

Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors

NCT04827459
View directory record Official record
Conditions
Insomnia, Breast Cancer, Prostate Cancer, Colon Cancer
Interventions
Sleep Coach App
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Phase 2 Interventional

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

NCT00146055
View directory record Official record
Conditions
Myeloma, Plasma-Cell, Lymphoma, Malignant, Myeloproliferative Disorders, Myelodysplastic Syndromes, Waldenstrom's Macroglobulinemia
Interventions
Reduced intensity conditioning with allogeneic transplant
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 13, 2026, 8:23 PM EDT
Active, not recruiting Not applicable Interventional

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

NCT04396808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher, Prolaris, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score)
Device · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
8
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional

Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine

NCT00176761
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Interleukin-2 (IL-2)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 13, 2026, 8:23 PM EDT
Recruiting Not applicable Interventional

Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma

NCT07630155
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Analgesic Agent, Electronic Health Record Review, Lidocaine Topical, Medical Device Usage and Evaluation, Survey Administration, Ureteroscopy
Drug · Other · Device + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated Phase 3 Interventional Results available

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

NCT04503668
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Not applicable Interventional

Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer

NCT06073223
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Usual Care, CQUPLE
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated No phase listed Observational

Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage

NCT00156260
View directory record Official record
Conditions
Breast Cancer
Interventions
Ductal lavage
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional Results available

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

NCT00615589
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
Fludarabine/Busulfan x 4 days, stem cell transplant
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 13, 2026, 8:23 PM EDT
Recruiting Phase 1 Interventional

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

NCT06914479
View directory record Official record
Conditions
Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm
Interventions
Ad-hCMV-Flt3L, Ad-hCMV-TK, Biospecimen Collection, Magnetic Resonance Imaging, Survey Administration, Tumor Resection, Valacyclovir
Genetic · Procedure · Other + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years to 39 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

NCT01188889
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
RAD001, Imatinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 13, 2026, 8:23 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT06784336
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant
Interventions
Iron chelation, Potato Resistant Starch
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Recruiting Phase 2 Interventional

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

NCT04858256
View directory record Official record
Conditions
T-Cell Neoplasm, Lymphoproliferative Disorders
Interventions
Pacritinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 13, 2026, 8:23 PM EDT